Bristol-Myers Squibb Delivers Excellent Second Quarter
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced double-digit sales growth in a quarter that was highlighted by important new product approvals in both the U.S. and Europe, and key data from the Company's cardiovascular, oncology and diabetes franchises.
NCCN Receives $2M Educational Grant from Pfizer
- Details
- Category: Pfizer
The National Comprehensive Cancer Network® (NCCN®) announces the development of the first continuing medical education (CME) program to leverage data in the NCCN Oncology Outcomes Database (NCCN Database) to objectively measure the impact of comprehensive performance improvement on patient outcomes.
Pfizer Reports Second-Quarter 2011 Results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today reported financial results for second-quarter 2011. Second-quarter 2011 revenues were $17.0 billion, a decrease of 1% compared with the year-ago quarter.
Sanofi's sales growth of 6.9% thanks to Genzyme acquisition
- Details
- Category: Sanofi
Sanofi's total sales grew 6.9% to €8,349 million. Excluding Genzyme, sales were down 4.0% reflecting €778 million of sales lost due to generic competition vs. Q2 2010. Growth platforms grew by 9.5% and including Genzyme accounted for 65.2% of total sales.
Bayer continues positive momentum
- Details
- Category: Bayer
Sales of the Bayer Group grew by 0.8 percent in the second quarter to EUR 9,252 million (Q2 2010: EUR 9,179 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 5.4 percent. Business performance in the emerging markets made an above-average contribution to this development.
Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010.
AstraZeneca PLC Second quarter and half year results 2011
- Details
- Category: AstraZeneca
AstraZeneca's revenue in the second quarter was down 2 percent at CER, but was up 3 percent on an actual basis as a result of the positive impact of exchange rate movements. This global revenue performance reflects government price interventions as well as the impact of more than $0.5 billion in revenue lost to generic competition, with the impact from generics in the US and Rest of World broadly similar.
More Pharma News ...
- "Roche Continents" at the Salzburg Festival celebrates its five-year anniversary
- Merck Total Revenues Increase by 16% to EUR 2.6 Billion
- Lilly Global Giving Puts Power of Philanthropy in Employees' Hands
- Roche to provide HIV/AIDS tests for Early Infant Diagnosis in South Africa
- New Senior Executives appointed at Sanofi
- Bristol-Myers Squibb to Acquire Amira Pharmaceuticals
- FDA approves new medicine BRILINTA (ticagrelor) for use in the US